Thursday, July 16, 2026

pharma · Diphtheria · Diabetes Mellitus, Type 2

Sanofi Pasteur MSD

Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini

France, LYON HQ
363 Employees
EMA registrant Type
Company details
Status
Public
HQ
France, LYON
Employees
363
Programs
83
Drugs
44
Patents
0
Clinical program

Japanese encephalitis vaccine

Phase 3 · mab · Japanese Encephalitis

Japanese encephalitis vaccine for Japanese Encephalitis is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

← All Sanofi Pasteur projects Phase 3 mab completed

Internal code JEC02

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sanofi Pasteur
Phase
Phase 3
Modality
mab
Indication
Japanese Encephalitis
Status
completed
Trials
1